Y-mAbs Therapeutics And Nobelpharma Entered Into An Exclusive License And Distribution Agreement For The Development And Commercialization In Japan Of Danyelza For Relapsed/Refractory High-risk Neuroblastoma And Potentially Relapsed Osteosarcoma, Y-mAbs Will Receive An Upfront Payment Of $2M And Is Entitled To Receive Up To $31M In Milestone Payments

Under the terms of the agreement, Nobelpharma will employ its regulatory, marketing, sales and access expertise to carry out development work and to submit DANYELZA for approval by Japanese regulatory authorities, and to market, sell, and distribute DANYELZA in Japan, if approved. Pursuant to the agreement, Y-mAbs will receive an upfront payment of $2.0 million from Nobelpharma in connection with entering into the agreement and is entitled to receive up to $31.0 million in product and commercial milestone payments in addition to profit sharing on commercial sales on DANYELZA, if successfully approved and commercialized in Japan.